TaBriX and UoM working with TB Alliance to develop novel drugs to treat drug-resistant tuberculosis
TaBriX is a new spin-out company from The University of Manchester (UoM) with the mission to create novel anti-virulence drugs to fight difficult-to-treat infections. TaBriX’s initial focus is on the treatment of drug-resistant TB. The team has developed a series… Read More »TaBriX and UoM working with TB Alliance to develop novel drugs to treat drug-resistant tuberculosis